A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The study is a randomized, double‐blind, and approved vaccine‐controlled Phase II booster study. It will evaluate the immunogenicity and safety of one dose of SCTV01C or SCTV01E as booster compared with one dose of Sinopharm inactivated COVID‐19 vaccine or one dose of Commirnaty as booster. The study will also evaluate the immunogenicity and safety of 2‐dose vaccinations (1‐dose of SCTV01C and 1‐dose of SCTV01E, or 2‐dose of SCTV01E, or 1‐dose of Sinopharm inactivated COVID‐19 vaccine and 1‐dose of SCTV01E, 1‐dose of Comirnaty and 1‐dose of SCTV01E).
Epistemonikos ID: 9e3173961e9c89690dac5dc8f796ec10826e62ab
First added on: Feb 16, 2022